Search

SGS518

SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

TAK-428

It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors. … TAK-428 is a drug for treating diabetic neuropathy.

2,3-Dimercapto-1-propanesulfonic acid

t-Butylhydroquinone

G17DT Immunogen

It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan … It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.

Hesperetin

Hesperetin, in the form of its glycoside [hesperidin], is the predominant flavonoid in lemons and oranges.

EHT899

It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load. … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection.

BOS172722

The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects. … BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent.

PH-284

PH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of appetite and cachexia in cancer and AIDS patients. … Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages.

NS-2359

This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.